--- title: Optimization and Testing Effectiveness of a Collaborative Intervention for School Attendance Problems in Norwegian Municipalities nct_id: NCT07463001 overall_status: NOT_YET_RECRUITING phase: NA sponsor: Norwegian University of Science and Technology study_type: INTERVENTIONAL primary_condition: School Attendance Problems countries: Norway canonical_url: "https://parkinsonspathways.com/agent/trials/NCT07463001.md" clinicaltrials_gov: "https://clinicaltrials.gov/study/NCT07463001" ct_last_update_post_date: 2026-03-10 last_seen_at: "2026-05-12T06:29:30.785Z" source: ClinicalTrials.gov (mirrored, no enrichment) --- # Optimization and Testing Effectiveness of a Collaborative Intervention for School Attendance Problems in Norwegian Municipalities **NCT ID:** [NCT07463001](https://clinicaltrials.gov/study/NCT07463001) ## Key Facts - **Status:** NOT_YET_RECRUITING - **Phase:** NA - **Study Type:** INTERVENTIONAL - **Target Enrollment:** 240 - **Lead Sponsor:** Norwegian University of Science and Technology - **Collaborators:** The Research Council of Norway, University of Tromso, University of Bergen, Regionsenter for barn og unges psykiske helse, Regionalt kunnskapssenter for barn og unge - Nord, NORCE Norwegian Research Centre AS, University of Stavanger, University of Aarhus - **Conditions:** School Attendance Problems - **Start Date:** 2026-03-23 - **Completion Date:** 2029-03-01 - **CT.gov Last Update:** 2026-03-10 ## Brief Summary In this study we will investigate the effects of an intervention called Back2School, revised and adapted for Norwegian conditions on school attendance. A total of 240 participants will be recruited. All participants who have been enrolled will receive the intervention. Half of the participants will receive the intervention without delay (the experiment group), and the other half will receive it following a 13-week period (the control group). Following consent, screening for eligibility and randomization, the intervention will start with an assessment related to the individual participant and condition at the participants' school. Based on this a shared understanding and an intervention plan is developed. Over a 13-week period the youth, the family and the school, work together guided by the municipal team to increase attendance and solve problems related to this. Assessments will be carried out after the intervention and 6 months later. ## Eligibility - **Minimum age:** 9 Years - **Maximum age:** 15 Years - **Sex:** ALL - **Healthy Volunteers:** No ``` Inclusion Criteria: 1. Participants must be between the ages of 9 and 15 at the time of enrollment. 2. Participants must have less than 80% attendance for the last 12 weeks of school at the time of screening. 3. At least one parent has to talk and understand Norwegian. 4. At least one parent has to be motivated to participate. 5. The school must agree to participate in the intervention Exclusion Criteria: 1 The participant has a known diagnosis of autism-spectrum disorder, psychosis, and/or eating disorder. 2\. Participant needs acute psychiatric intervention. ``` ## Arms - **Direct intervention** (EXPERIMENTAL) — Participants randomized to this intervention will receive the 13 week intervention Back2School starting immediately after randomization. - **Delayed intervention/ Wait list control** (OTHER) — Participants randomized to delayed intervention will ha to wait for 13-15 weeks following randomization before the intervention is started. During the waiting phase they can receive treatment as usual ## Interventions - **Back2School** (BEHAVIORAL) — The revised Back2S school manual consists of an initial assessment, a case formulation conference, 16 sessions and 3 meetings with different participants (parents, youth, school personnel) over 13 weeks. There is a booster session 12 weeks after the final session and one 24 weeks after the final session. ## Primary Outcomes - **School attendance** _(time frame: Direct: Avg at Baseline, 2 weeks at end (13 weeks from baseline), 2 weeks at 6 months (37 w from baseline) Delayed: Avg at baseline, 2 weeks before start (13 w from baseline) 2 weeks at end (28 w from baseline), 2 weeks at 6 months (54 w from baseline))_ — School attendance measured on a daily basis by teacher. - **General functioning** _(time frame: Direct start group: Will be measured at Baseline (T1), Week 15 from baseline (T2), Week 37 from baseline (T3) Delayed access group: Baseline (T1), Week 15 from Baseline (T1a), Week 29 from baseline (T2), Week 54 from baseline (T3))_ — Impact on daily life as measured by the SDQ impact scale ## Secondary Outcomes - **Change in Quality of life** _(time frame: Direct start group: Will be measured at Baseline (T1), Week 15 from baseline (T2), Week 37 from baseline (T3) Delayed access group: Baseline (T1), Week 15 from Baseline (T1a), Week 29 from baseline (T2), Week 54 from baseline (T3))_ - **Change in symptoms of anxiety** _(time frame: Direct start group: Will be measured at Baseline (T1), Week 15 from baseline (T2), Week 37 from baseline (T3) Delayed access group: Baseline (T1), Week 15 from Baseline (T1a), Week 29 from baseline (T2), Week 54 from baseline (T3))_ - **Change in symptoms of Depression** _(time frame: Direct start group: Will be measured at Baseline (T1), Week 15 from baseline (T2), Week 37 from baseline (T3) Delayed access group: Baseline (T1), Week 15 from Baseline (T1a), Week 29 from baseline (T2), Week 54 from baseline (T3))_ ## Locations (4) - NORCE, RKBU Vest, Bergen, Norway - Pilar, Regionsenter for barn og unges psykiske helse, Oslo, Norway - UIT, RKBU Nord, Tromsø, Norway - Norwegian University of Scinece and Technology, Trondheim, Norway ## Recent Field Changes (last 30 days) - `design.phases` — added _(2026-05-12)_ - `design.enrollmentCount` — added _(2026-05-12)_ - `status.overallStatus` — added _(2026-05-12)_ - `status.primaryCompletionDate` — added _(2026-05-12)_ - `status.completionDate` — added _(2026-05-12)_ - `status.lastUpdatePostDate` — added _(2026-05-12)_ - `eligibility.criteria` — added _(2026-05-12)_ - `eligibility.minAge` — added _(2026-05-12)_ - `eligibility.maxAge` — added _(2026-05-12)_ - `eligibility.sex` — added _(2026-05-12)_ - `outcomes.primary` — added _(2026-05-12)_ - `outcomes.secondary` — added _(2026-05-12)_ - `armsInterventions.arms` — added _(2026-05-12)_ - `armsInterventions.interventions` — added _(2026-05-12)_ - `sponsor.lead` — added _(2026-05-12)_ - `sponsor.collaborators` — added _(2026-05-12)_ - `results.hasResults` — added _(2026-05-12)_ - `locations.norce, rkbu vest|bergen||norway` — added _(2026-05-12)_ - `locations.pilar, regionsenter for barn og unges psykiske helse|oslo||norway` — added _(2026-05-12)_ - `locations.uit, rkbu nord|tromsø||norway` — added _(2026-05-12)_ - `locations.norwegian university of scinece and technology|trondheim||norway` — added _(2026-05-12)_ --- *Canonical: https://parkinsonspathways.com/agent/trials/NCT07463001.md* *Source data (authoritative): https://clinicaltrials.gov/study/NCT07463001* *This page is a raw mirror with no AI summary, no editorial enrichment, and no Parkinson's-specific filtering.*